Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q1 2024 Earnings Call Transcript May 13, 2024 8:00 AM ET
Company Participants
Alex Sapir - CEO and President
Alan Musso - CFO
Paul Bruno - SVP of Business and Corporate Development
Iain Fraser - SVP of Early Development
Conference Call Participants
Edward Tenthoff - Piper Sandler
Gregory Renza - RBC Capital Markets
Corinne Johnson - Goldman Sachs
Joseph Schwartz - Leerink Partners
Dae Gon Ha - Stifel
Matthew Biegler - Oppenheimer
Operator
Good morning and welcome to Fulcrum Therapeutics' First Quarter 2024 Financial Results and Business Update Conference Call. Currently, all participants are in a listen-only mode. This call is being webcast live and can be accessed on the Investors section of Fulcrum's website at www.fulcrumtx.com and is being recorded.
Please be reminded that remarks made during this call may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These may include statements about the company's future expectations and plans, clinical development, timelines, and financial projections. While these forward-looking statements represent Fulcrum's views as of today, this should not be relied upon as representing the company's views in the future. Fulcrum may update these statements in the future, but it's not taking on an obligation to do so. Please refer to Fulcrum's most recent filings with the Securities and Exchange Commission for a discussion of certain risks and uncertainties associated with the company's business.
Leading the call today will be Alex Sapir, CEO and President of Fulcrum. Joining Alex on the call are Alan Musso, Chief Financial Officer; Dr. Iain Fraser, Senior Vice President of Early Development; and Paul Bruno, Senior Vice President of Business and Corporate Development. After providing updates on our key programs, there will be a brief Q&A in which Alex, Alan, Iain, and Paul will be available to answer your questions.
With that, it's my pleasure to turn the call over to Alex.
Alex Sapir
That's great. Thanks, Shannon. And thanks to all of you for joining us on the call this morning. Beyond another solid quarter of progress across our two clinical stage assets, losmapimod and pociredir, we are super excited to announce our collaboration and license agreement with Sanofi for the development and commercialization of losmapimod.
So what I'd like to start off by doing this morning is just provide an overview of the structure and strategic importance of this collaboration with Sanofi. In brief, Sanofi will obtain exclusive commercialization rights for losmapimod outside of the US and that will allow Fulcrum to focus our efforts on planning for a strong US commercial launch in 2026. This collaboration allows both parties to do what we each do best. It combines Fulcrum’s expertise in FSHD with Sanofi's exceptional regulatory development and commercial capabilities across approximately 100 countries outside the US. Importantly, having a partner like Sanofi will allow us to reach patients in ex-US markets quicker than we could do on our own and mitigates the commercial execution risk that is typically inherent for any biotech company undertaking the commercial launch of its first product on its own. We believe we have selected the best possible partner for losmapimod, and we look forward to delivering on our shared commitment to addressing the unmet need of patients with FSHD.